ATE287732T1 - Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden - Google Patents

Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden

Info

Publication number
ATE287732T1
ATE287732T1 AT95930196T AT95930196T ATE287732T1 AT E287732 T1 ATE287732 T1 AT E287732T1 AT 95930196 T AT95930196 T AT 95930196T AT 95930196 T AT95930196 T AT 95930196T AT E287732 T1 ATE287732 T1 AT E287732T1
Authority
AT
Austria
Prior art keywords
cell lines
retroviral vectors
human serum
lysis
production cell
Prior art date
Application number
AT95930196T
Other languages
English (en)
Inventor
Michael Pensiero
Mary K L Collins
Francois-Loic Cosset
Yasuhiro Takeuchi
Robin A Weiss
Original Assignee
Genetic Therapy Inc
Cancer Res Inst Royal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Therapy Inc, Cancer Res Inst Royal filed Critical Genetic Therapy Inc
Application granted granted Critical
Publication of ATE287732T1 publication Critical patent/ATE287732T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT95930196T 1994-08-17 1995-08-17 Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden ATE287732T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29176594A 1994-08-17 1994-08-17
US45121595A 1995-05-26 1995-05-26
PCT/US1995/010496 WO1996004934A1 (en) 1994-08-17 1995-08-17 Retroviral vectors produced by producer cell lines resistant to lysis by human serum

Publications (1)

Publication Number Publication Date
ATE287732T1 true ATE287732T1 (de) 2005-02-15

Family

ID=26966960

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95930196T ATE287732T1 (de) 1994-08-17 1995-08-17 Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden

Country Status (7)

Country Link
US (2) US5952225A (de)
EP (1) EP0769968B1 (de)
JP (1) JPH10507905A (de)
AT (1) ATE287732T1 (de)
CA (1) CA2196208A1 (de)
DE (1) DE69533959D1 (de)
WO (1) WO1996004934A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0769968B1 (de) * 1994-08-17 2005-01-26 Genetic Therapy, Inc. Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US6117681A (en) * 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
CA2237000A1 (en) * 1995-11-08 1997-05-15 The Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
CA2238434A1 (en) * 1995-12-15 1997-06-19 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
WO1998000541A2 (en) * 1996-07-03 1998-01-08 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
US20040019923A1 (en) * 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
JP2002509695A (ja) * 1997-11-21 2002-04-02 ゲセルシャフト フュア バイオテクノロギッシェフォーシュング エムベーハー（ゲーベーエフ） 一本鎖ｄｎａ又は二本鎖ｄｎａ、コード化融合タンパク質，ウイルス，パッケージング細胞及びこれらの使用ヒト補体システムによる不活化に耐えるウイルスの開発
US6743631B1 (en) * 1998-03-17 2004-06-01 North Shore University Hospital Research Corporation Use of human serum resistant vector particles and cell lines for human gene therapy
GB0400443D0 (en) * 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
GB0122803D0 (en) * 2001-09-21 2001-11-14 Oxford Biomedica Ltd Vector
CA2371216A1 (en) * 1999-04-23 2000-11-02 Centre For Translational Research In Cancer Pseudotyped retroviral vector for gene therapy of cancer
US6849454B2 (en) 2000-03-07 2005-02-01 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles
WO2001066150A2 (en) * 2000-03-07 2001-09-13 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cel ls by rd114 pseudotyped retroviral vector particles
WO2002044394A2 (en) 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
WO2003048311A2 (en) * 2001-11-29 2003-06-12 Institutes For Pharmaceutical Discovery, Llc Regulated expression of recombinant dna
US7015035B2 (en) * 2002-11-05 2006-03-21 The Trustees Of Columbia University In The City Of New York RD114-based retroviral packaging cell line and related compositions and methods
US20070178066A1 (en) * 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
JP5546716B2 (ja) * 2004-09-29 2014-07-09 タカラバイオ株式会社 レトロウイルスベクター産生用細胞
US20060292159A1 (en) * 2005-06-08 2006-12-28 Ranscht Barbara E Methods for the inhibition of neovascularization and cancer metastasis
EP2967078B1 (de) 2013-03-14 2018-10-17 GenVivo, Inc. Thymidinkinase-diagnosetest für gentherapieanwendungen
CA3242916A1 (en) * 2022-01-07 2025-02-27 Universite De Namur METHODS FOR EVALUATING RESISTANCE TO NON-INTEGRATIVE VIRAL VECTORS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
WO1992005266A2 (en) * 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
US5470726A (en) * 1991-02-22 1995-11-28 Fred Hutchinson Cancer Research Center Retrovirus packaging and producer cell lines based on gibbon ape leukemia virus
WO1993025698A1 (en) * 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
WO1994017478A1 (en) * 1993-01-19 1994-08-04 City Of Hope Method for control of chaotic systems
DE69434860T2 (de) * 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
EP0769968B1 (de) * 1994-08-17 2005-01-26 Genetic Therapy, Inc. Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden

Also Published As

Publication number Publication date
WO1996004934A1 (en) 1996-02-22
EP0769968B1 (de) 2005-01-26
JPH10507905A (ja) 1998-08-04
CA2196208A1 (en) 1996-02-22
US6329199B1 (en) 2001-12-11
EP0769968A1 (de) 1997-05-02
EP0769968A4 (de) 1997-10-29
US5952225A (en) 1999-09-14
DE69533959D1 (de) 2005-03-03

Similar Documents

Publication Publication Date Title
DE69533959D1 (de) Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden
ATE237312T1 (de) In liposomen verkapselte nukleinsäurekomplexe
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
BR9910251A (pt) Estimulação hematopoiética
PT1053256E (pt) Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
BG103664A (en) Pharmaceutical forms containing ammoxycillin and clavulanate
FI963103A0 (fi) Ei-virusvektori
ATE312190T1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
EP1361271A3 (de) Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen
CA2278028A1 (en) Methods for improving transformation efficiency
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
AU2236795A (en) Afamin: a human serum albumin-like protein
ATE193733T1 (de) Stahl für die herstellung von teilbaren maschinenteilen und maschinenteile, hergestellt aus diesen stahl
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
AU6682594A (en) Treatment of septic shock
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
FR2742048B1 (fr) Utilisation de l'alpha-cyano-beta, beta-diphenylacrylate de 2-ethylhexyle pour ameliorer la stabilite de compositions cosmetiques contenant le p-methyl-benzylidene camphre en association avec un derive de dibenzoylmethane
MX9806041A (es) Proteina purificada sr-p70.
ATE348158T1 (de) Neuartiges collectin
CA2047802A1 (en) Pharmaceutical compositions
DE3877808D1 (de) Eisenoxidkatalysator und dessen herstellung.
CA2108358A1 (en) Gene expression in bacilli
BR9609801A (pt) Petídos cíclicos análogos de somatostina com atividade inibitória do desenvolvimento de hormónio
EP0868908A3 (de) Kosmetisches Mittel
CA2222718A1 (en) Attachment enhanced 293 cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties